US federal regulation

2021 looks set to be a big year for cannabis reform in the US now that the new White House administration has signalled that cannabis reform is one of its top priorities, and the US public supports cannabis reform in unprecedented numbers.

Keep up to date with the latest changes in federal regulation impacting the US market for CBD market with news, data and research at the CBD-Intel hub.

The Future of CBD in Europe post novel food regulations

12th May 2021 - Presentations , Resources |

Tim Phillips, CBD-Intel’s managing director, recently presented at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 28th April 2021. In addition to an overview of the impact of Covid-19 on the retail environment, he provided a comparative analysis of the current Novel Food legislation in the UK and the US, as […]

What impact do Democrat victories in both of the Georgia senate seat elections have on chances for cannabis reform at the US federal level?

8th January 2021 - Blog |

President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would […]

In December 2018 the Farm Bill removed hemp – defined as cannabis – and its derivatives, from the definition of marijuana in the Controlled Substances Act.

This paved the way for the legal cultivation, sale and distribution of the hemp plant but also led to led to the misperception that all products made from or containing hemp, including those made with CBD, were now legal to sell in interstate commerce.

Two years on, there is still a lack of clarity around what is and isn’t legal and the CBD industry is held back by lack of federal regulation and a patchwork of consumer and products safety standards and guidance.
Industry stakeholders have called for more joined up regulation, including increased protection of state legalisation frameworks, access to banking for cannabis firms, harmonised standards for consumer and product safety and lab testing, and relaxation of federal constraints on research.

With frustrations mounting over the Food and Drug Administration’s (FDA’s) slow pace, Congress could take matters into its own hands by passing legislation to move the industry forward.

Though Biden himself seemingly remains sceptical about recreational cannabis – having previously stated it should be placed in Schedule II under the Controlled Substances Act category – many of his major appointments appear to be solid supporters of hemp and cannabis, which gives the industry reason for optimism.

Stay on top of the ever-changing regulatory landscape with our CBD-Intel hub, which provides access to our news briefings, data and reports on developments related to US federal regulation.